Bonnet F, Balkau B, Malécot J M, Picard P, Lange C, Fumeron F, Aubert R, Raverot V, Déchaud H, Tichet J, Lecomte P, Pugeat M
Endocrinology Unit, Department of Medicine, CHU Rennes, Université Rennes 1, INSERM U625, 35000 Rennes, France.
Eur J Endocrinol. 2009 Jul;161(1):81-5. doi: 10.1530/EJE-09-0202. Epub 2009 May 8.
Previous evidence has suggested that a low sex hormone-binding globulin (SHBG) concentration is associated with insulin-resistance and a low adiponectin concentration. We investigated the association between SHBG and the risk of hyperglycemia in each sex and we determined potential interactions between SHBG and adiponectin levels in the development of dysglycemia.
We used a nested case-control design in the large prospective study, Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). We studied 227 men and women who were normoglycemic at baseline but hyperglycemic at 3 years (glycemia > or = 6.1 mmol/l or type 2 diabetes). They were matched for sex, age, and body mass index with 227 subjects who remained normoglycemic at 3 years.
At baseline, the concentration of SHBG was significantly lower in women who subsequently developed hyperglycemia than in those who remained normoglycemic, with no difference for men. In multiple regression, SHBG at baseline was as an independent determinant of plasma adiponectin levels, in both women (P<0.0001) and men (P=0.002). In multivariate conditional logistic regression taking into account physical activity and changes in waist circumference over the follow-up, plasma SHBG remained significantly associated with the development of hyperglycemia in women but not in men. These associations persisted after adjustment for fasting insulinemia, high fasting glucose, and adiponectin levels.
These findings suggest that a low SHBG level is a strong risk marker for dysglycemia in women, independently of both adiponectinemia and insulinemia. SHBG may therefore improve the identification of women at risk of diabetes.
先前的证据表明,低性激素结合球蛋白(SHBG)浓度与胰岛素抵抗及低脂联素浓度相关。我们研究了SHBG与各性别高血糖风险之间的关联,并确定了在血糖异常发展过程中SHBG与脂联素水平之间的潜在相互作用。
我们在大型前瞻性研究“胰岛素抵抗综合征流行病学研究(DESIR)”中采用了巢式病例对照设计。我们研究了227名男性和女性,他们在基线时血糖正常,但在3年后出现高血糖(血糖≥6.1 mmol/L或2型糖尿病)。他们在性别、年龄和体重指数方面与227名在3年后仍保持血糖正常的受试者相匹配。
在基线时,随后发生高血糖的女性中SHBG浓度显著低于血糖保持正常的女性,男性则无差异。在多元回归分析中,基线时的SHBG是血浆脂联素水平的独立决定因素,在女性(P<0.0001)和男性(P=0.002)中均如此。在考虑了体力活动和随访期间腰围变化的多变量条件逻辑回归分析中,血浆SHBG在女性中仍与高血糖发展显著相关,而在男性中则不然。在调整空腹胰岛素血症、高空腹血糖和脂联素水平后,这些关联依然存在。
这些发现表明,低SHBG水平是女性血糖异常的一个强有力的风险标志物,独立于脂联素血症和胰岛素血症。因此,SHBG可能有助于改善对糖尿病风险女性的识别。